IMMU Key Statistics, Chart & Performance
The current stock price of IMMU is 87.86 null. In the past month the price increased by 3%. In the past year, price increased by 442.35%.
About IMMU
Company Profile
Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or `naked` form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.
Company Info
Immunomedics Inc
300 AMERICAN RD
MORRIS PLAINS NJ 07950
CEO: Usama Malik
Phone: 973-605-8200
Immunomedics Inc / IMMU FAQ
What does Immunomedics Inc do?
Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or `naked` form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.
Can you provide the latest stock price for Immunomedics Inc?
The current stock price of IMMU is 87.86 null. The price increased by 0.05% in the last trading session.
Does Immunomedics Inc pay dividends?
IMMU does not pay a dividend.
How is the ChartMill rating for Immunomedics Inc?
IMMU has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is Immunomedics Inc (IMMU) stock traded?
IMMU stock is listed on the Nasdaq exchange.
Can you provide the market cap for Immunomedics Inc?
Immunomedics Inc (IMMU) has a market capitalization of 20.31B null. This makes IMMU a Large Cap stock.
IMMU Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IMMU. When comparing the yearly performance of all stocks, IMMU is one of the better performing stocks in the market, outperforming 99.45% of all stocks.
IMMU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMMU. IMMU has a great financial health rating, but its profitability evaluates not so good.
IMMU Financial Highlights
Over the last trailing twelve months IMMU reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS decreased by -40.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1760.55% | ||
| ROA | -32.81% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |